Skip to main content
. Author manuscript; available in PMC: 2020 Nov 14.
Published in final edited form as: Leukemia. 2020 May 14;34(11):2981–2991. doi: 10.1038/s41375-020-0858-1

Figure 3. The combination of dasatinib and quizartinib decreases STAT5 activation in CM and overcomes stroma-based resistance to FLT3 TKI.

Figure 3.

A. MOLM-13 cells cultured in CM were treated with quizartinib 10 nM alone or in combination with fixed doses (0.1 μM) of various inhibitors. Following 4 hours of culture, cells were harvested and STAT5 phosphorylation was assessed by flow cytometry. (n=3) B. Cell proliferation assay in MOLM-13 cells cultured in CM and treated with graded doses of quizartinib alone or in combination with fixed doses (0.1 μM) of inhibitors for 72 hours. (n=3) C and D. STAT5, Lyn and Src activation in MOLM-13 cells following culture in RM or CM and treatment with quizartinib ± dasatinib for 4 hours.